Loading clinical trials...
Loading clinical trials...
Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes
Conditions
Interventions
Ruxolitinib
Hydroxyurea (HU)
+2 more
Locations
70
United States
Scottsdale, Arizona, United States
Fayetteville, Arkansas, United States
Burbank, California, United States
Glendale, California, United States
La Jolla, California, United States
Los Angeles, California, United States
Start Date
June 1, 2012
Primary Completion Date
March 1, 2014
Completion Date
May 1, 2016
Last Updated
November 14, 2017
NCT07357727
NCT06976918
NCT06343805
NCT05123365
NCT06327100
NCT06063486
Lead Sponsor
Incyte Corporation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions